LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Kodu・Aktsiate loetelu・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Suletud

SektorTervishoid

12.75 6.07

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

11.81

Max

12.93

Põhinäitajad
By Trading Economics
Sissetulek	4.4M -18M
Müük	3.4M 18M
Kasumimarginaal	-99.678
Töötajad	131
EBITDA	5.6M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+40.96% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	24. nov 2025

Turustatistika
By TradingEconomics
Turukapital	193M 332M
Eelmine avamishind	6.68
Eelmine sulgemishind	12.75

Uudiste sentiment

By Acuity

30%

70%

78 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

5.04 / 5.44 Toetus ja vastupanu

ENANTA PHARMACEUTICALS INC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. nov 2025, 18:59 UTC

Suurimad hinnamuutused turgudel

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17. nov 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17. nov 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17. nov 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17. nov 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17. nov 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q Rev $2.6B >TCOM

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q EPS $4.02 >TCOM

17. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. nov 2025, 21:40 UTC

Tulu

James Hardie Industries 2Q Adj EPS 26c >JHX

17. nov 2025, 21:40 UTC

Tulu

James Hardie Industries 2Q Loss/Shr 10c >JHX

17. nov 2025, 21:39 UTC

Tulu

James Hardie Industries 2Q Sales $1.29B >JHX

17. nov 2025, 21:38 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 21:38 UTC

Tulu

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17. nov 2025, 21:10 UTC

Tulu

XP Inc. 3Q EPS BRL2.47 >XP

17. nov 2025, 21:10 UTC

Tulu

XP Inc. 3Q Rev BRL4.67B >XP

17. nov 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17. nov 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17. nov 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. nov 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17. nov 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17. nov 2025, 19:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 18:20 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17. nov 2025, 16:45 UTC

Omandamised, ülevõtmised, äriostud

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17. nov 2025, 16:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 16:15 UTC

Tulu

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17. nov 2025, 15:40 UTC

Omandamised, ülevõtmised, äriostud

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17. nov 2025, 15:22 UTC

Omandamised, ülevõtmised, äriostud

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17. nov 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Võrdlus sarnastega

Hinnamuutus

ENANTA PHARMACEUTICALS INC Prognoos

Hinnasiht

By TipRanks

40.96% tõus

12 kuu keskmine prognoos

Keskmine 17 USD 40.96%

Kõrge 24 USD

Madal 9 USD

Põhineb 6 Wall Streeti analüütiku instrumendi ENANTA PHARMACEUTICALS INC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi ENANTA PHARMACEUTICALS INC aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.04 / 5.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

78 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.